The company now focuses on filing the valbenazine new drug application as they prepare for the commercial launch of the drug for the treatment of tardive dyskinesia.Neurocrine's expenses have risen steadily since May 2015, primarily due to the pre-commercialization activities for valbenazine.
The company now focuses on filing the valbenazine new drug application as they prepare for the commercial launch of the drug for the treatment of tardive dyskinesia.Neurocrine's expenses have risen steadily since May 2015. This was primarily due to the pre-commercialization activities for valbenazine.